Compare Coupang Inc (CPNG) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Quest Diagnostics Inc — how do they compare? Coupang Inc trades at $15.82 (market cap $27.70B), while Quest Diagnostics Inc trades at $230.97 (market cap $25.48B). The key difference: Coupang Inc and Quest Diagnostics Inc are close in size by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Coupang Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Quest Diagnostics Inc for 56 Days on average.
| CPNG | DGX | |
|---|---|---|
Market Cap | $27.70B | $25.48B |
Volume | 27,703,608 | 941,866 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $247.45 |
52-Week Low | $13.75 | $173.49 |
Typical Hold Time | 55 Days | 56 Days |
Enterprise Value | $27.22B | $31.23B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $15.41, up 4.05% today, with a bullish technical signal and strong analyst support. Revenue grew to $34.53B in 2025, though recent quarterly EPS misses and a negative net income margin of -2.16% highlight profitability challenges. The stock is supported by positive cash flow from operations of $1.77B and a dominant e-commerce position in South Korea, but faces competitive pressure and a projected net loss in 2026.
The outlook balances high growth potential against near-term earnings volatility. Investment appeal lies in market dominance and analyst consensus price target of $25.25, implying significant upside, but risks include intense competition, regulatory scrutiny from U.S.-South Korea trade tensions (CNBC, 2026-08-31), and execution hurdles in expanding logistics networks.
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
